
    
      All patients in this trial will receive the investigational (chemotherapy) drug at an optimal
      dose as determined by previous clinical trials. The investigational drug is given through a
      vein once every three weeks. This drug prevents tumor cells from dividing, so they may stop
      growing or die.
    
  